Leo Hermle

2.2k total citations
40 papers, 1.6k citations indexed

About

Leo Hermle is a scholar working on Clinical Psychology, Psychiatry and Mental health and Cognitive Neuroscience. According to data from OpenAlex, Leo Hermle has authored 40 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Clinical Psychology, 12 papers in Psychiatry and Mental health and 10 papers in Cognitive Neuroscience. Recurrent topics in Leo Hermle's work include Psychedelics and Drug Studies (13 papers), Schizophrenia research and treatment (10 papers) and Forensic Toxicology and Drug Analysis (7 papers). Leo Hermle is often cited by papers focused on Psychedelics and Drug Studies (13 papers), Schizophrenia research and treatment (10 papers) and Forensic Toxicology and Drug Analysis (7 papers). Leo Hermle collaborates with scholars based in Germany, Switzerland and United States. Leo Hermle's co-authors include Sabine Maier, Manfred Spitzer, Euphrosyne Gouzoulis‐Mayfrank, Euphrosyne Gouzoulis, Karl‐Artur Kovar, G. Oepen, Brendan A. Maher, K.‐A. Kovar, Elmar Habermeyer and B. Thelen and has published in prestigious journals such as Biological Psychiatry, Journal of Abnormal Psychology and Neuropsychopharmacology.

In The Last Decade

Leo Hermle

39 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leo Hermle Germany 19 703 623 473 436 203 40 1.6k
Theo Huber Switzerland 8 821 1.2× 293 0.5× 558 1.2× 102 0.2× 257 1.3× 8 1.3k
R. Andrew Sewell United States 22 546 0.8× 256 0.4× 727 1.5× 279 0.6× 278 1.4× 36 1.8k
Erich Studerus Switzerland 27 1.5k 2.2× 650 1.0× 783 1.7× 962 2.2× 611 3.0× 76 2.9k
Ede Frecska Hungary 20 724 1.0× 265 0.4× 539 1.1× 561 1.3× 225 1.1× 80 1.8k
Oliver G. Bosch Switzerland 19 431 0.6× 440 0.7× 379 0.8× 104 0.2× 182 0.9× 36 1.3k
Jörg Daumann Germany 30 894 1.3× 555 0.9× 911 1.9× 365 0.8× 54 0.3× 55 2.2k
DJ Nutt United Kingdom 15 432 0.6× 198 0.3× 357 0.8× 140 0.3× 156 0.8× 35 1.2k
David Nutt United Kingdom 29 342 0.5× 480 0.8× 1.3k 2.8× 307 0.7× 102 0.5× 72 2.5k
Tomáš Páleníček Czechia 25 1.0k 1.5× 299 0.5× 1.2k 2.5× 299 0.7× 446 2.2× 84 2.4k
U. McCann United States 14 1.3k 1.9× 153 0.2× 795 1.7× 94 0.2× 494 2.4× 17 1.9k

Countries citing papers authored by Leo Hermle

Since Specialization
Citations

This map shows the geographic impact of Leo Hermle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leo Hermle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leo Hermle more than expected).

Fields of papers citing papers by Leo Hermle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leo Hermle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leo Hermle. The network helps show where Leo Hermle may publish in the future.

Co-authorship network of co-authors of Leo Hermle

This figure shows the co-authorship network connecting the top 25 collaborators of Leo Hermle. A scholar is included among the top collaborators of Leo Hermle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leo Hermle. Leo Hermle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hermle, Leo, et al.. (2017). Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 81. 1–10. 85 indexed citations
2.
Hermle, Leo & Rainer Kraehenmann. (2016). Experimental Psychosis Research and Schizophrenia—Similarities and Dissimilarities in Psychopathology. Current topics in behavioral neurosciences. 36. 313–332. 10 indexed citations
3.
Hewer, Walter, H. S. Füeßl, & Leo Hermle. (2011). Körperliche Erkrankungen bei psychiatrischen Patienten. Fortschritte der Neurologie · Psychiatrie. 79(6). 358–372. 2 indexed citations
4.
Ruchsow, Martin, et al.. (2010). MRT als Lügendetektor und Gedankenleser?. Der Nervenarzt. 81(9). 1085–1091. 1 indexed citations
5.
Kiefer, Markus, Ulla Martens, Matthias Weisbrod, Leo Hermle, & Manfred Spitzer. (2009). Increased unconscious semantic activation in schizophrenia patients with formal thought disorder. Schizophrenia Research. 114(1-3). 79–83. 41 indexed citations
6.
Grunze, Heinz, Florian Seemüller, Sandra Dittmann, et al.. (2007). Risperidone monotherapy in manic inpatients: An open label, multicentre trial. The World Journal of Biological Psychiatry. 8(4). 256–261. 5 indexed citations
7.
Spitzer, Manfred, Henrik Walter, Arthur Wunderlich, et al.. (2001). Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans. Neuropharmacology. 41(2). 263–271. 41 indexed citations
8.
Riemann, Dieter, Armin König, Fritz Hohagen, et al.. (1999). How to preserve the antidepressive effect of sleep deprivation: A comparison of sleep phase advance and sleep phase delay. European Archives of Psychiatry and Clinical Neuroscience. 249(5). 231–237. 72 indexed citations
9.
Gouzoulis‐Mayfrank, Euphrosyne, B. Thelen, Elmar Habermeyer, et al.. (1999). Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d -methamphetamine in healthy volunteers. Psychopharmacology. 142(1). 41–50. 105 indexed citations
10.
Gouzoulis‐Mayfrank, Euphrosyne, et al.. (1998). Hallucinogenic drug induced states resemble acute endogenous psychoses: results of an empirical study. European Psychiatry. 13(8). 399–406. 51 indexed citations
11.
Gouzoulis‐Mayfrank, Euphrosyne, et al.. (1998). History, Rationale and Potential of Human Experimental Hallucinogenic Drug Research in Psychiatry. Pharmacopsychiatry. 31(S 2). 63–68. 31 indexed citations
12.
Hermle, Leo, Euphrosyne Gouzoulis‐Mayfrank, & Matthew W. Spitzer. (1998). Blood Flow and Cerebral Laterality in the Mescaline Model of Psychosis. Pharmacopsychiatry. 31(S 2). 85–91. 32 indexed citations
13.
Hermle, Leo, et al.. (1997). Metachromatische Leuko- dystrophie mit dem klinischen Erscheinungsbild einer schizophrenieähnlichen Psychose. Der Nervenarzt. 68(9). 754–758. 1 indexed citations
14.
Hermle, Leo, Euphrosyne Gouzoulis‐Mayfrank, & Manfred Spitzer. (1996). Halluzinogen-induzierte psychische Störungen. Fortschritte der Neurologie · Psychiatrie. 64(12). 482–491.
15.
Hermle, Leo, et al.. (1993). Psychological Effects of MDE in Normal Subjects. Neuropsychopharmacology. 8(2). 171–176. 65 indexed citations
16.
Hermle, Leo, et al.. (1992). Beziehungen der Modell- bzw. Drogenpsychosen zu schizophrenen Erkrankungen. Fortschritte der Neurologie · Psychiatrie. 60(10). 383–392. 11 indexed citations
17.
Kovar, Karl‐Artur, et al.. (1990). Synthetische Suchtstoffe der 2. Generation (sog. Designer Drugs) 1. Mitt.: Amphetamine und andere Arylalkanamine. Pharmazie in unserer Zeit. 19(3). 99–107. 9 indexed citations
18.
Oepen, G., et al.. (1989). Right hemisphere involvement in mescaline-induced psychosis. Psychiatry Research. 29(3). 335–336. 14 indexed citations
19.
Hermle, Leo, G. Oepen, & Manfred Spitzer. (1988). Zur Bedeutung der Modellpsychosen* **. Fortschritte der Neurologie · Psychiatrie. 56(2). 48–58. 8 indexed citations
20.
Kohler, J., Andreas Hufschmidt, Leo Hermle, Balázs Volk, & C. H. Lücking. (1988). Limbic encephalitis: two cases. Journal of Neuroimmunology. 20(2-3). 177–178. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Theo Huber Breakdown of academic impact, for papers by R. Andrew Sewell Breakdown of academic impact, for papers by Erich Studerus Breakdown of academic impact, for papers by Ede Frecska Breakdown of academic impact, for papers by Oliver G. Bosch Breakdown of academic impact, for papers by Jörg Daumann Breakdown of academic impact, for papers by DJ Nutt Breakdown of academic impact, for papers by David Nutt Breakdown of academic impact, for papers by Tomáš Páleníček Breakdown of academic impact, for papers by U. McCann
Rankless by CCL
2026